Healthcare Global Enterprises · NSE: HCG · BSE: 539787
Q2 FY22 results · Jul–Sep 2021
Healthcare Global Enterprises reported revenue from operations of ₹351.96 crore (up 42.0% from Q2 FY21) and net profit of ₹98.99 crore for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 351.96 | 247.92 | +42.0% | 323.14 | +8.9% |
| Other income | 3.30 | 4.01 | −17.7% | 3.44 | −4.1% |
| Total income | 355.26 | 251.93 | +41.0% | 326.58 | +8.8% |
| Profit before share of associates & JVs and tax | 143.91 | (32.29) | Turned profit | (9.49) | Turned profit |
| Share of profit/(loss) of associates & JVs | (2.00) | 0.44 | 0.57 | ||
| Net profit for the period | 98.99 | (26.56) | Turned profit | (12.52) | Turned profit |
| Attributable to shareholders of the company | 103.09 | (22.29) | Turned profit | (9.57) | Turned profit |
| EPS, basic (₹) | 8.22 | (1.94) | Turned profit | (0.76) | Turned profit |
| Net margin (%) | 28.1 | -10.7 | -3.9 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 215.66 | 145.56 | +48.2% | 200.60 | +7.5% |
| Other income | 1.54 | 5.56 | −72.3% | 4.53 | −66.0% |
| Total income | 217.20 | 151.12 | +43.7% | 205.13 | +5.9% |
| Profit before tax | 132.70 | (12.23) | Turned profit | 1.93 | 69x |
| Net profit for the period | 93.90 | (6.58) | Turned profit | 1.40 | 67x |
| EPS, basic (₹) | 7.49 | (0.57) | Turned profit | 0.11 | 68x |
| Net margin (%) | 43.5 | -4.5 | 0.7 |
Consolidated
- Filed with BSE
- 11 Nov 2021, 18:21 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2021, 18:21 IST
- Board meeting
- 11 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE